Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company has market cap of $484.96 million. The firm is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. It currently has negative earnings. The Company’s lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis.
Analysts expect Five Prime Therapeutics, Inc. (NASDAQ:FPRX) to report $-1.29 EPS on February, 22.They anticipate $0.56 EPS change or 76.71% from last quarter’s $-0.73 EPS. After having $-1.54 EPS previously, Five Prime Therapeutics, Inc.’s analysts see -16.23% EPS growth. The stock decreased 0.42% or $0.08 during the last trading session, reaching $19.09. About 465,687 shares traded. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has declined 30.56% since February 15, 2017 and is downtrending. It has underperformed by 47.26% the S&P500.
Investors sentiment increased to 1.04 in Q3 2017. Its up 0.34, from 0.7 in 2017Q2. It improved, as 14 investors sold Five Prime Therapeutics, Inc. shares while 34 reduced holdings. 18 funds opened positions while 32 raised stakes. 23.96 million shares or 0.77% more from 23.78 million shares in 2017Q2 were reported. New York State Common Retirement Fund reported 30,600 shares. Platinum Invest has 0.02% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Moreover, Ameritas Prtn has 0% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 2,330 shares. Ascend Cap stated it has 0.08% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Pnc Fincl Group accumulated 0% or 6 shares. Doheny Asset Mngmt Ca has 6,150 shares. Parametric Associate Limited Liability Com invested in 26,889 shares. Proshare Advsr Limited Liability Company, a Maryland-based fund reported 18,149 shares. Fifth Third Bank has 0% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Renaissance Tech has invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Invesco Ltd holds 0% or 14,498 shares in its portfolio. Rhumbline Advisers owns 34,672 shares. Alliancebernstein Lp has invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). 16 are held by Sei. Envestnet Asset Mgmt reported 52 shares or 0% of all its holdings.
Since September 28, 2017, it had 0 buys, and 2 sales for $148,468 activity. RINGO WILLIAM R sold $76,000 worth of stock.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. The company has market cap of $649.26 million. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. It currently has negative earnings. The Company’s product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors.
Among 10 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Five Prime Therapeutics had 21 analyst reports since July 31, 2015 according to SRatingsIntel. As per Monday, June 5, the company rating was maintained by BMO Capital Markets. The stock of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has “Sell” rating given on Tuesday, August 11 by Zacks. The firm earned “Buy” rating on Wednesday, June 7 by Jefferies. Wells Fargo maintained the shares of FPRX in report on Friday, December 4 with “Outperform” rating. The rating was upgraded by Zacks on Friday, August 21 to “Sell”. The rating was initiated by Citigroup with “Buy” on Friday, July 31. The firm has “Outperform” rating by BMO Capital Markets given on Tuesday, November 7. Jefferies maintained Five Prime Therapeutics, Inc. (NASDAQ:FPRX) rating on Monday, September 11. Jefferies has “Buy” rating and $52.0 target. Oppenheimer maintained the stock with “Outperform” rating in Monday, October 19 report. The company was maintained on Monday, November 6 by RBC Capital Markets.
The stock increased 3.15% or $0.27 during the last trading session, reaching $9. About 266,418 shares traded. Cytokinetics, Incorporated (CYTK) has risen 88.33% since February 15, 2017 and is uptrending. It has outperformed by 71.63% the S&P500.
Ratings analysis reveals 100% of Cytokinetics’s analysts are positive. Out of 2 Wall Street analysts rating Cytokinetics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $21.0 while the high is $22.0. The stock’s average target of $21.50 is 138.89% above today’s ($9) share price. CYTK was included in 2 notes of analysts from December 16, 2016. The firm earned “Overweight” rating on Friday, December 16 by Cantor Fitzgerald. The firm earned “Strong Buy” rating on Monday, February 6 by Needham.